Vitamin D: Effect on Haematopoiesis and Immune System and Clinical Applications

Mayte Medrano, Estrella Carrillo-Cruz, Isabel Montero and Jose A Perez-Simon

Department of Hematology, University Hospital Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), Universidad de Sevilla, 41013 Sevilla, Spain; mayte_md26@hotmail.com (M.M.); estrellacarrillocruz@gmail.com (E.C.-C.); icas3760@hotmail.com (I.M.)

* Correspondence: josea.perez.simon.sspa@juntadeandalucia.es; Tel.: +34-955013260

Received: 6 August 2018; Accepted: 4 September 2018; Published: 8 September 2018

Abstract: Vitamin D is a steroid-like hormone which acts by binding to vitamin D receptor (VDR). It plays a main role in the calcium homeostasis and metabolism. In addition, vitamin D display other important effects called “non-classical actions.” Among them, vitamin D regulates immune cells function and hematopoietic cells differentiation and proliferation. Based on these effects, it is currently being evaluated for the treatment of hematologic malignancies. In addition, vitamin D levels have been correlated with patients’ outcome after allogeneic stem cell transplantation, where it might regulate immune response and, accordingly, might influence the risk of graft-versus-host disease. Here, we present recent advances regarding its clinical applications both in the treatment of hematologic malignancies and in the transplant setting.

Keywords: vitamin D; haematopoiesis; leukaemia; myelodysplastic syndrome; allogeneic stem cell transplantation

1. Vitamin D: Metabolism and Mechanisms of Action

1.1. Production and Metabolism of Vitamin D

Vitamin D (vit D) is a fat-soluble steroid synthesized in several steps which ends with the formation of vit D3 or calcitriol, the most active form of vit D. It is known for its role in the regulation of calcium and phosphorus levels as well as bone mineralization. The term vitamin D is imprecise and groups together different components that are part of this family of steroid hormones. Firstly, pre-D3 is produced in the skin from 7-dehydrocholesterol after exposure to ultraviolet irradiation. Besides, this irradiation also produces lumisterol and tachysterol from pre-D3. The synthesis of lumisterol is a reversible process and can be converted back to pre-D, which binds to Vitamin D-binding protein (DBP) and is subsequently removed from the skin. Pre-D3 has to be hydroxylated twice to became fully activated. The first hydroxylation occurs in the liver and, to a lesser extent, in other tissues by 25-hydroxylase (CYP2R1) to produce 25(OH)D. This is the principal circulating form of vit D and provides a clinically useful marker for vit D status. In the kidney, the enzyme CYP27B1 hydroxylates 25(OH)D, which is then converted into 1,25(OH)D. This process is stimulated by parathyroid hormone and inhibited by calcium, phosphate and fibroblast growth factor 23 (FGF-23). CYP27B1 can be also found in other tissues including epithelial cells, immune cells and parathyroid glands. The extrarenal production of 1,25(OH)D is under a different control, mainly by cytokines such as tumour necrosis factor α (TNFα) and interferon γ (IFNγ). In the kidney, the catalytic enzyme CYP24A1 is the responsible for the inactivation of 1,25(OH)D producing 24,25(OH)D [1]. Several oxidative reactions after 24-hydroxilation and conjugation with glucuronic acid generate some compounds that are excreted through the bile.
The balance between 1α-hydroxylase and 24-hydroxylase activities is regulated by calcitriol, calcium and phosphate serum levels. Parathyroid hormone (PTH) stimulates the synthesis of the 1α-hydroxylase under low serum calcium conditions or low levels of vitamin D, resulting in the increase of 1,25(OH)D activation. PTH also inhibits 24-hydroxylase and can induce osteoclast and osteocytes synthesis of the FGF-23, which acts by reducing the expression of renal sodium-phosphate transporters and regulates vitamin D homeostasis by suppressing renal expression of 1α-hydroxylase and inducing 24-hydroxylase, thus reducing serum calcitriol levels and subsequently serum calcium under hyperphosphatemia conditions [2].

After ultra violet (UV) exposure, maximum levels of vit D are achieved. From that moment, UV irradiation further converts pre-D to lumisterol and tachysterol preventing higher levels to be reached (Figure 1) [3,4]. Also, the amount of melanin in the epidermis can modify the effectiveness of the sunlight in producing pre-D3 [5].

Figure 1. Synthesis of vitamin D and the vitamin D metabolic pathway. The vitamin D metabolites are transported in blood bound primarily to vitamin D binding protein (DBP) (85–88%) and albumin (12–15%).

1.2. Vitamin D Receptor (VDR)

Vit D operates via binding vitamin D receptor (VDR). Vit D-VDR heterodimerize with retinoid-X-receptor (RXR) within the cell nucleus where it binds vitamin D responsive elements (VDRE) to serve as a transcription factor for numerous target genes. VDR/RXR complexes can attract co-activators or co-repressors to induce or repress gene transcription, depending on the target gene. Steroid receptor coactivator (SRC) and vitamin D receptor interacting protein (DRIP) complex have been identified as coactivators [6]. SRC coactivators recruit histone acetyl transferases (HAT) to the gene promoting transcription. In addition to acetylation, histone methylation also occurs. Recent studies have shown that methyltransferases may also play a role in VDR-mediated transcription [7]. The DRIP complex acts as a bridge between VDRE and the initiation complex (TATA box, RNA polymerase II and other proteins) to facilitate transcription. Co-repressors of VDR function act in the absence of ligand or in the presence of antagonists. The most studied corepressors for VDR are the nuclear
receptor corepressor (NCoR) and the silencing mediator for retinoid or thyroid-hormone receptors (SMRT) \[8,9\].

1,25(OH)D can also inhibit gene transcription via VDR or inhibiting directly other transcription factors. VDR can also functions un-liganded to 1,25(OH)D. As an example, it modulates mammalian hair cycling in keratinocytes by regulating genes such as CASP14, S100A8, SOSTDC1 \[10\].

The VDR has a very short N-terminal domain when compared to other nuclear hormone receptors. The human VDR has two potential starting sites. A common polymorphism (FokI) alters the first ATG start site to ACG when contains the C genotype (formerly F) instead of T (formerly f). Individuals with C genotype begin translation three codons downstream resulting in a VDR protein three amino acids shorter (424 instead of 427 aa). It has been demonstrated in transfection experiments that the short isoform produces a more potent immune response as it resulted in a higher nuclear factor κB (NF-κB)- and nuclear factor of activated T-cells (NFAT)-driven transcription and a higher IL-12 expression in dendritic cells and monocytes \[11\]. This polymorphism has also been correlated with a reduced bone \[12\]. The DNA binding domain is comprised of two zinc fingers. The proximal (N-terminal) zinc finger is a specific site to bind to the VDREs whereas the second zinc finger serves for heterodimerization to the retinoid X receptor (RXR). The second half of the molecule is the ligand binding domain, where it binds 1,25(OH)D, which also contains regions required for heterodimerization to RXR. The major activation domain, AF-2, is located at the C-terminal end, which is critical for the binding to coactivators \[6\].

2. Effect of Vitamin D on the Immune System

In addition to its effect on calcium metabolism, vit D plays other important physiological roles. These effects are called “non-classical actions” and were identified 30 years ago, when receptors for 1,25-dihydroxyvitamin D3 (1,25(OH)\(_2\)D3) were detected in several cell lines \[13–15\]. In fact, VDR is present in most cells types, which explains its wide range of effects \[16\]. As previously mentioned, vit D is primarily involved in calcium and phosphate homeostasis. Besides, vit D has other functions, such as regulation of hormone secretion. More specifically, 1,25(OH)D stimulates insulin and thyroid-stimulating hormone (TSH) secretion. Pancreatic β cells have CYP27B1, VDR and calbindin-D. Studies with calbindin-D null mice suggest that it modulates depolarization-stimulated insulin release \[17,18\].

Vitamin D is also implicated in the regulation of proliferation and differentiation of cells. As an example, vit D is involved in normal breast development and in hepatic cell growth. 1,25(OH)D collaborates in the maturation of type II epithelial pneumocytes by increasing phospholipid production and surfactant release and stimulates the innate immune response in bronchial epithelial cells \[19\]. Vit D stimulates calcium uptake by cardiac muscle cell \[20\], which is necessary to the contractility. It has been reported that vit D deficiency is associated with increased risk of myocardial infarction in men \[21\]. Vit D is also essential for skeletal muscle function. Therefore, vit D deficiency produce proximal muscle weakness \[22\].

Within the spectrum of non-classical effects of vitamin D, actions on cells of the immune system are included \[23,24\]. In patients with granulomatous diseases such as sarcoidosis, high levels of 1,25(OH)\(_2\)D3 and hypercalcemia are observed. An increase in the enzyme 25-hydroxyvitamin D-1-α-hydroxylase (1α-hydroxylase) is also observed. Unlike normal subjects, in whom the activity of this enzyme is located in the kidney, in patients with sarcoidosis, activity is also observed in macrophages \[25–28\]. The deregulation of 1,25(OH)\(_2\)D3 is not restricted to sarcoidosis but is a common feature in many granulomatous diseases \[29\]. The precise nature of the interaction between vitamin D and the immune system took many years to identify and there are still many questions about this interaction.
2.1. Vitamin D and Innate Immunity

2.1.1. Macrophages, Vitamin D and Cathelicidin

Macrophages and monocytes play a key role in the initiation of non-specific responses to pathogenic organisms or tissue damage. This role consists in phagocytizing pathogens or cellular debris and then eliminating or assimilating the material.

For many years it was thought that the most important action of vitamin D on macrophages was due to its ability to stimulate the differentiation of monocytic precursors to mature macrophages [23,30–32]. This concept was supported by observations that showed different expression of the vitamin D receptor (VDR) and α-1 hydroxylase in the different stages of differentiation of macrophages. Some studies show that human macrophages are able to synthesize 1,25(OH)2D3 upon exposure to IFNγ [33,34]. The confirmation of this effect on monocytes was obtained by Modlin et al. who described genes involved in innate immunity regulation which are specifically modulated in monocytes by Mycobacterium tuberculosis. VDR and the gene coding for 1-α-hydroxylase (CYP27B1) are induced through the “toll like” 2/1 receptor pathway (TLR 2/1). The interaction of TLR 2/1 with the precursor of vitamin D (25(OH)D3) stimulates the expression of the antibacterial protein cathelicidin [35]. Regulation of the transcription of cathelicidin by binding VDR to 25(OH)D3 is possible because its promoter gene contains a functional VDRE. This element is only present in the most developed primates, which is suggestive that the regulation of vitamin D in this facet of innate immunity is a recent event of evolutionary development [36,37]. The precise mechanism by which TLR activation induces the expression of VDR and 1-α-hydroxylase is not clear. The analysis of the events involved in the transcripational regulation of CYP27B1 suggests that the interaction with TLR involves the JAK/STAT pathway, the MAP kinases and NF-κB and that all of this occurs in synergy with the induction of CYP27B1 by IFNγ [38]. Other studies propose that the induction of CYP27B1 by TLR2/1 occurs indirectly through IL-15 and IL17A. The enzyme 24-hydroxylase, whose function is to inactivate 1,25(OH)2D3, is encoded by a gene (CYP24) that is induced by 25(OH)D3 after activation by TLR2/1 in monocytes [38,39].

In summary, vitamin D is a potent stimulator of the mechanisms associated with the elimination of pathogens and the appearance of this system in primates (including early Homo sapiens), exposed to abundant amounts of sunlight, was an evolutionary advantage. In fact, it is a system that has key control mechanisms; not only has a catabolic enzyme, 24-hydroxylase, which attenuates the responses to 1,25(OH)2D3 but also feedback mechanisms. In this regard, 1,25(OH)2D3 is a potent down-regulator of TLR2 and TLR4 in monocytes, decreasing inflammatory responses. Hence, using CYP24 and TLR regulatory mechanisms, vitamin D helps to promote innate immune responses by preventing tissue damage associated with excessive inflammation [40,41].

2.1.2. Dendritic Cells and Antigenic Presentation

Dendritic cells (DC) are responsible for the presentation of antigens, resulting from the elimination of pathogens and tissue debris, to cells belonging to adaptive immunity.

Myeloid dendritic cells (M-DCs) produce high levels of IL-12, whereas high levels of IFN are secreted by plasmacytoid dendritic cells (P-DCs) with distinct effects on activation and differentiation of T-cell [42].

Dendritic cells participate in immune responses producing both immunogenic and tolerogenic phenotype. Immature DCs, by the expression of inhibitory receptors, induce anergy among CD4+ cells and elicit generation of IL-10 producing Tregs cells [43]. The tolerogenic activity of immature DC may also be related to the expression of endocytic manose receptors (MR), which can deliver negative signals to T-cells. MR levels are up-regulated by anti-inflammatory molecules such as corticosteroids, vit D, Th2 cytokines (IL-4 and IL-3) and are down-regulated by proinflammatory stimuli (IFN-α). At the same time, Tregs are capable of maintaining the tolerogenic state by inhibiting myeloid DC maturation, reducing their antigen-presenting function and decreasing IL-12 secretion [44].
The expression of VDR in purified dendritic cells was reported for the first time in 1987 [45]. Studies carried out subsequently purifying skin dendritic cells (Langerhans cells) showed that 1,25(OH)₂D₃ could attenuate the effect of antigen presentation [46]. However, the role of vitamin D and its metabolites was not elucidated until the advent of dendritic cell models derived from monocytes. In the year 2000, Gauzzi et al. showed that 1,25(OH)₂D₃ and its synthetic analogues inhibited the maturation of dendritic cells derived from monocytes, suppressing their ability to present antigens to T cells, suggesting vitamin D could promote tolerance [47–49]. This concept was evaluated in pancreatic islet transplant models in which a lower rejection rate was observed in mice treated with vitamin D [50]. This response seems to be due to a decreased maturation of DC and a concomitant involvement of suppressor T lymphocytes or regulatory T cells [51].

Overall, vit D induces DCs tolerogenicity due to the capacity to inhibit differentiation, maturation, costimulatory molecule expression and IL-12 production, leading to decreased allostimulatory capacity while enhancing IL-10 secretion which favours the induction of regulatory T cells. Vit D not only inhibits DC differentiation and maturation but also transform differentiated IFN-DC into a more immature stage [47].

1,25(OH)₂D₃ preferentially affects myeloid dendritic cells. Although some studies suggest an apparent insensitivity of plasmacytoid dendritic cells to 1,25(OH)₂D₃, it is possible that the local synthesis of vitamin D by these cells could participate in the mechanism of tolerogenicity through the VDR receptor expressed in T cells [52,53].

2.2. Vitamin D and Adaptive Immunity

2.2.1. Vitamin D and T Lymphocytes

Non-activated T cells express undetectable levels of VDR, while receptor expression increases upon T cell activation. Overall, vit D could limit the potential tissue damage associated with Th1 immune responses. However, the validity of this generalization was questioned in mouse models in which vit D was able to inhibit the cytokines associated with both Th1 (INFγ) and Th2 (IL-4) [54–58]. In addition, it is interesting to note that in animal models of inflammatory bowel disease, the treatment with vit D reduces the expression of IL-17 [59,60]. Hence, it is possible that vit D exerts its effects on inflammation and autoimmune disease also through the regulation of Th17 cells. Finally, vitamin D also affect regulatory T cells. In this regard, in 2002, it was shown that 1,25(OH)₂D₃ in conjunction with steroids stimulated the production of IL-10 by the CD4+ CD25+ regulatory T cells [51,61]. Other studies indicate that vitamin D produces a preferential T-regulatory differentiation [62,63]. Accordingly, vitamin D stimulates the secretion of IL-10 and TLR9 by regulatory T cells, which connects immune and adaptive responses [64].

In contrast to the wide effect on CD4+ T cells, CD8+ T cells show a poor response to 1,25(OH)₂D₃ [65–68]. Despite their significant expression of VDR, 1,25(OH)₂D₃ does not have a significant impact on CD8+ lymphocytes, as shown in animal models of autoimmune encephalomyelitis [69,70].

In addition to its effect on certain T cell populations, recent studies show that vitamin D may also have an effect on the phenomenon of “homing” or tropism of T cells by specific tissues [71]. Some studies suggest that vitamin D inhibits the migration of T cells to lymph nodes. It might also have an effect on T cell homing into the skin by upregulating the cytokine receptor (CCR10), whose ligand CCL27 is expressed by epidermal keratinocytes. This effects on the phenomenon of “homing” is produced by both 25(OH)D₃ and by 1,25(OH)₂D₃ and several authors suggest that both dendritic cells and T lymphocytes are the source of 1x hydroxylase activity [72]. By contrast, vitamin D exert a negative effect on cytokines and their receptors in the gastrointestinal tract [73].
2.2.2. Vitamin D and B Lymphocytes

In addition to the classical function of B lymphocytes as precursors of plasma cells that produce antibodies and, therefore, as a cellular subtype in which humoral immunity rests, populations of B lymphocytes whose main function is the production of IL-10 have been described that could correspond to regulatory B subpopulations. Some animal models of autoimmune diseases have revealed that the regulatory B cells produce IL-10 and can suppress inflammatory processes. IL-10 derived from B cells seems to be important for the generation and maintenance of regulatory T cells. In models in which the maturation of B cells is blocked, there is a reduced capacity for the induction of tolerance and this inability is associated with inadequate potential for the generation of FoxP3+ regulatory T cells. These findings are corroborated by murine models of arthritis in which the deficiency of IL-10 derived from B cells exacerbates the disease and correlates with low levels of regulatory T cells, which are restored with the transfer of IL-10 producing B cells [74–81]. Deficits in the function and frequency of regulatory B cells have been reported in multiple sclerosis and systemic lupus erythematosus [82–85].

Like T cells, active B cells express VDR. As shown in experimental studies, B cells at rest have low but detectable levels of mRNA for VDR [86,87]. After incubation with anti CD40/IL-21, an increase in VDR expression is observed. The addition of 1,25(OH)$_2$D3 increases the expression of VDR mRNA. VDR is functional in activated B cells [85] while the mRNA for CYP24A1 is not detectable in B cells at rest [88]. Activated B cells are therefore able to metabolize vitamin D and respond to its active component.

Initial studies indicated that 1,25(OH)$_2$D3 could regulate the production of B cells and the secretion of immunoglobulins [89]. Studies in which purified B cells are cultivated in the presence of vitamin D show a decrease in the percentage and absolute number of plasma cells as well as IgA, IgG and IgM levels, the results being contradictory with IgE [90–95]. The formation of memory B lymphocytes is also inhibited by 1,25(OH)$_2$D3. Therefore, the effects of vitamin D on B cells could be summarized as a decrease in the “pool” of memory B cells and inhibition of the generation of plasma cells, with the consequent decrease in the secretion of antibodies. On naïve B cells, constitutively expressing VDR and CYP27B1, the response to vitamin D consists in an increase of the expression of VDR, of 25(OH)D3 and of the degrading enzyme of 1,25(OH)$_2$D3 CYP24A1. After activation, the expression of VDR and CYP27B1 does increase, which also results in an increase of the level of 1,25(OH)$_2$D3 and stimulates the negative feedback mechanism through the increase of CYP24A1 [85]. The participation of regulatory B cells in the immune homeostasis exerted by vitamin D seems to be confirmed in murine models of autoimmune diseases in which a functioning pathway mediated by IL-10 is required to guarantee the effect of 1,25(OH)$_2$D3 on the disease [96,97].

2.3. Genetic Fingerprint of Vitamin D in the Immune System

Deep genomic analysis has allowed to define a new perspective on vitamin D and its function in humans. In macrophages, the description of increased levels of VDR and 1α hydroxylase (CYP27B1) after a pathogenic challenge underscored the importance of the intracrine system of vitamin D as a mediator of the immune response [34,98]. It is now known that macrophages and dendritic cells are capable of responding to 25(OH)D3, the largest circulating metabolite of vitamin D, which provides a link between these cells and vitamin D in humans. The identification of hundreds of target genes for 1,25(OH)$_2$D3 in immune cells has also provided a new perspective on the role of vitamin D in the adaptive immune system [33].

The first study based on genome assays focused on vitamin D was published by John White and colleagues at McGill University in Montreal and used a combination of DNA arrays on genes regulated by 1,25(OH)$_2$D3 and strategies in silico [26,27,33,99–103]. The deep analysis of the target sequences that are capable of binding to VDR reveals response elements (VDRE) that are located next to genes that promote antibacterial proteins such as cathelicidin (CAMP) and β defensin 2 (DEFB4). Only CAMP seems to be induced transcriptionally in monocytes [104]. The underlying mechanism for the differential regulation of CAMP and DEFB4 by 1,25(OH)$_2$D3 was determined in subsequent
studies. The first one described the increased expression in monocytes of DEFB4 after treatment with 1,25(OH)\(_2\)D\(_3\) and IL-1. This required the cooperative occupation of VDRE by NF-κB and, on the other hand, the binding of VDRE with the DEFB4 promoter gene [104].

The importance of NF-κB and VDR as co-inductors of the transcription of β defensin 2 (DEFB4) was subsequently reinforced in studies focused on the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) protein [105]. Cells treated with 1,25(OH)\(_2\)D\(_3\) and the NOD ligand multidrug resistance (MDR), derived from microorganisms, show a potent induction of DEFF4 dependent on NF-κB [36,37]. However, the induction of CAMP is primarily dependent on the binding of VDR to the VDRE promoter. The VDRE element initially identified as the CAMP promoter appears to be specific to human and subhuman primates [106]. The acquisition of a VDRE element for the CAMP gene seems to have occurred due to the introduction of a nuclear element (SINE) that put CAMP under the control of the VDR receptor. This specific adaptation of primates has been conserved in humans and in primates of the Old and New World, suggesting that CAMP’s regulatory transcriptional mechanism for vitamin D confers biological advantages. It is assumed that this mechanism could be potently activated by the relatively high levels of 25(OH)D\(_3\) and 1,25(OH)\(_2\)D\(_3\) that are characteristic of non-human primates.

Recognition and response to pathogens involves the identification of molecular patterns associated with pathogen surveillance (PAMPs) through pattern recognition receptors (PRRs), including the extensive family of “Toll like” receptors (TLR), noncatalytic transmembrane proteins that interact with specific PAMPs [35]. In genomic studies on models of tuberculous infection, the TLR 2/1 stimulus induces the expression of CY27B1 and VDR, suggesting that the endocrine system of vitamin D is involved in the macrophagic response to Mycobacterium tuberculosis. The macrophages treated with ligand TLR1/2 are reactive to the 1,25(OH)\(_2\)D\(_3\) and 25(OH)D\(_3\) forms of vitamin D, confirming the functional efficacy of the intracrine model.

The stimulation of TLR1/2 by Mycobacterium tuberculosis also produces the induction of the catabolic enzyme of vitamin D (CYP24A1) and the antibacterial protein CAMP. The expression of the other antibacterial protein DEFB4 is a result of the cooperative action between the TLR1/2, II-1, NOD2 MDP pathway. Antibacterial proteins such as CAMP and DEFB4 play a crucial role in bacterial intracellular death mediated by vitamin D. Monocytes treated with increasing concentrations of the CAMP peptide show a dose-dependent reduction of internalization of Mycobacterium tuberculosis and a similar inhibition in macrophages occurs in presence of 25(OH)D\(_3\), this effect being interrupted by the VDR antagonists [37]. Vitamin D and its analogues are capable of promoting autophagy, this induction being very important to provoke antibacterial responses through vitamin D in the tuberculous infection [107].

The intracrine synthesis of 1,25(OH)\(_2\)D\(_3\) seems to regulate the expression of another antibacterial protein, hepcidin (HAMP) [107,108]. The major function attributed to HAMP seems to be the suppression of the membrane protein ferroportin, the only intracellular iron exporter. This link in cells such as enterocytes, hepatocytes and monocytes play a key role in the so-called chronic process anaemia [107]. Iron restriction from the circulation provides an important host response to systemic infection, although for pathogens such as Mycobacterium tuberculosis, that evades immune surveillance at the intracellular level, iron accumulation might favour the growth of intracellular pathogens. Vitamin D in its forms 25(OH)D\(_3\) and 1,25(OH)\(_2\)D\(_3\) suppress the transcription of HAMP in monocytes and hepatocytes, which leads to the release of the blockade to ferroportin dependent on HAMP, favouring the transport of iron and decreasing its intracellular concentration [109].

Neutrophils express VDR but, unlike monocytes and macrophages, they do not seem to express a functional 1α-hydroxylase enzyme and are not subject to an intracrine activation of the vitamin D system [110].

Dendritic cells, which belong to the same hematopoietic lineage of monocytes and macrophages, express VDR and CYP27B1 and exhibit an active intracrine system of vitamin D [45,110,111]. As discussed above, dendritic cells use a paracrine system of vitamin D, in which differentiation
into antigen-presenting cells implies an increase in CYP27B1 and, paradoxically, a decrease in VDR expression [112]. Therefore, immature cells express VDR and respond to 1,25(OH)\(_2\)D\(_3\) produced by mature cells, with low expression of VDR. Such mechanism pursues the maturation of the dendritic cell and the promotion of T activation and prevents the over-elaboration of the immune response.

In mice, CD8 cells express the activating enzyme of vitamin D, 1-\(\alpha\)-hydroxylase [67]. However, in experimental models of autoimmune diseases mediated by CD8 lymphocytes, vitamin D does not seem to play any role. CD8\(\alpha\)\(\alpha\), a variant of CD8 T cells and vitamin D are tied and play a role in the suppression of gastrointestinal inflammation [113].

2.4. Vitamin D Levels and Immune Function

Most of the deep genomic analyses that explore the immunomodulatory effects of vitamin D in vitro have focused on the use of 1,25(OH)\(_2\)D\(_3\) or its synthetic analogues. However, the induction by pathogens of an intracrine system such as that of monocytes/macrophages suggests that in vivo regulation is independent of 1,25(OH)\(_2\)D\(_3\). Probably, this system is initially driven by the local activation of 25(OH)D3, the predominant circulating form of vitamin D.

Epidemiological studies have shown that insufficient levels of vitamin D (serum levels below 30 ng/mL) are associated with an increased risk of tuberculosis [114–117]. Clinical trials with vitamin D supplements added to conventional antibiotics have shown variable success. When 10,000 IU of vitamin D were used daily, serum vitamin D levels increased in tuberculous patients but it did not improve the efficacy of the treatment as compared to patients included in the placebo arm. However, in a specific subgroup of patients with a single Taq1 nucleotide polymorphism in the VDR gene, this reduction was demonstrated, suggesting that genetic factors may influence the immune response to vitamin D supplementation [118].

The link between vitamin D and infection is not restricted to patients with tuberculosis. Among patients with sepsis, circulating levels of 25(OH)D3 are correlate with serum concentrations of CAMP and also correlates with poor prognosis [119,120]. Low levels of 25(OH)D3 are linked to respiratory infections such as influenza and, in patients with chronic renal failure, are correlated with an increased rate of infection and mortality [121]. The application of deep genomic analysis to assess the impact of serum vitamin D status on immune function is limited [122]. In animal models, deep analysis of immune responses has been attempted [123]. Mice deficient in vitamin D showed a decreased expression of angiogenin 4, an antibacterial protein that acts by minimizing the invasion of tissues by enteric bacteria. This leads to higher levels of bacteria in the colon epithelium [124]. This deregulation is related with tissue inflammation in inflammatory bowel diseases and, accordingly, vitamin D could protect from this inflammation by inducing the antibacterial protein angiogenin 4 [125].

A recent study of almost 34,000 individuals shows that genetic variations in DBP influence on the serum concentrations of the DBP protein which, in turn, are linked to the total serum levels of 25(OH)D3 and 1,25(OH)\(_2\)D\(_3\). The genetic variations of the DBP protein could be related to different affinities of 25(OH)D3 with the DBP protein [126–128]. The antibacterial responses to 25(OH)D3 are more pronounced with forms of low affinity BPD involving high free levels of 25(OH)D3 [129,130].

3. Vitamin D in Haematopoiesis and Hematopoietic Stem Cells

The physiologically active form of vitamin D, 1,25-dihydroxycholecalciferol or 1,25(OH)\(_2\)D\(_3\) promote monocytic differentiation of HL60, a human promyelocytic leukaemia cell line [131,132]. It is also well recognized that 1,25(OH)\(_2\)D\(_3\) induces normal mononuclear blood cells to differentiate towards the monocyte-macrophage route of maturation [133]. Studies in vitro shown that vitamin D suppresses colony formation of normal human granulocyte macrophage progenitors (CFU-GM) and, by contrast, induces differentiation of colonies into monocyte-macrophages [134]. Experiments with hematopoietic stem cells and leukemic cell lines treated with the active form of vitamin D demonstrate an increase in monocyte/macrophage differentiation and an increase in the number of mature cells that is not evident in mice lacking VDR [135–137]. After its binding to the vitamin D
analogue, VDR forms a homodimer or binds to the retinoid X receptor (RXR), which proceeds to interact with VDRE originating a transcription signal on several effector RNAs [56,136]. In addition to RXR, VDR can also bind to the retinoic acid receptor (RAR) which promotes the differentiation of mature granulocytes [138]. Experiments with cell cultures suggest that activated RAR and VDR compete for their binding to RXR and the relative balance between the RAR/RXR and VDR/RXR dimers influences the relative activity of granulopoiesis or monopoiesis [139]. In animal models, the lack of VDR and RAR allows the generation of appropriate monocyte and granulocyte colony forming units, with which it is suspected that the primary effect of vitamin D occurs on cytokine signalling and on the final stages of differentiation of these two cell types.

The complexity of the interaction between VDR and RXR has been reflected in recent observations in which it is shown that retinoic acid and vitamin D can potentiate their action mutually, so that VDR stimulation seems to increase in the presence of RAR-binding. RXR [136].

Studies with VDR knockout (KO) mice showed that the lack of VDR does not affect the normal haematopoiesis and mice presented normal relative numbers of red and white blood cells. By contrast, the addition of vitamin D derivatives can influence at later stages of haematopoiesis [56,140]. 1,25(OH)₂D₃ activates certain intracellular signalling pathways, which have been suggested to intersect at a common nodal point, Raf-1, such as: lipid signalling pathways (protein kinase C pathway), the phosphatidylinositol-3-kinase (PI3K)-AKT pathway and mitogen activated kinase (MAPK) pathways (Figure 2) [131,141].

![Figure 2](image_url). 1,25(OH)₂D₃ acts mediating lipid signalling pathways (protein kinase C pathway), phosphatidylinositol-3-kinase (PI3K)-AKT pathway and mitogen activated kinase (MAPK) pathways.

Regarding the lipid signalling pathway, vitamin D can increase the activity of sphingomyelinase and protein kinase C (PKC) [131,141]. The latter can influence on signal transduction through MAPK pathways. In addition, PKC is an important mediator of hematopoietic cell differentiation [142].

Lipid signalling pathways involve sphingomyelinase, whose activity increases in HL-60 cells treated with 1,25(OH)₂D₃, leading to increased ceramide levels and enhancement of vitamin D-induced differentiation [143,144].

1,25(OH)₂D₃ can activate PI3K-AKT pathway, involved in the formation of a VDR/PI3K complex in a signalling pathway that parallels the MAPK pathways, which mediate cell differentiation.
LY294002, a PI3K inhibitor, inhibits 1,25(OH)$_2$D$_3$-induced monocytic cell marker CD14 and CD11b expression in THP-1 cells, demonstrating the implication of PI3K pathway in promoting differentiation [145,146]. Vitamin D has also been proposed to induce differentiation by disassembling AKT-Raf1 complex, upregulating Raf1 and activating the Raf/MEK/ERK MAPK pathway.

Three different MAPK signalling cascades are implicated in 1,25(OH)$_2$D$_3$-induced cell growth arrest and differentiation: Raf-1/MEK/ERK MAPK, JNK/MAPK and p38/MAPK pathways [131].

With regards to lymphopoiesis, Yu et al. demonstrated, using a VDR KO mice lacking vitamin D, that the expression of the vitamin D receptor (VDR) is required for normal thymic development and function of invariant Natural Killer T (iNKT) cells, which are intrinsically defective and lack T-bet expression. In vitro studies showed an inhibitory effect of vitamin D on NK cell development, while promoting myeloid differentiation. However, analysis of CD4 and CD8 T cells and regulatory T cells numbers in the thymus identified no differences between wild type (WT) and VDR KO mice [73,147,148].

VDR KO mice present an extramedullary haematopoiesis because of abnormal bone mineralization [149]. Hematopoietic defects such as anaemia, extramedullary haematopoiesis, thrombocytopenia, myelofibrosis and myelodysplasia was exhibited by children with vitamin D deficiency-associated rickets [150]. 1,25(OH)$_2$D$_3$ affects embryonic hematopoietic stem and progenitor cell (HSPC) numbers in vivo and in vitro via VDR-mediated regulation of pro-proliferative responses independent of Ca$^{2+}$ flux [150].

1,25(OH)$_2$D$_3$ negatively influences hemogenic endothelial formation independent of VDR activation by antagonizing Hedgehog signalling [151]. Ex vivo treatment with 1,25(OH)$_2$D$_3$ increased the proliferation, survival and multi-lineage colony forming activity of CD34+ human umbilical cord blood hematopoietic stem cells (HSCs) [150].

4. Clinical Applications

4.1. Use of Vitamin D in the Treatment of Hematologic Malignancies

Due to the aforementioned effects on maturation, vitamin D and its analogues have been used as treatment in myeloid neoplasms, particularly myelodysplastic syndromes (MDS) and acute myeloblastic leukaemias (AML). Specific preclinical experiences with HL-60 and other leukaemic lines, such as U-937 and THP-1, have shown differentiation and apoptosis of blasts with vitamin D, suggesting that these components, such as all-trans retinoic acid (ATRA) in acute promyelocytic leukaemia (APL), reverse the blockade of the differentiation of myeloblasts [131,136,141].

The anti-leukemic activity of vitamin D was described almost three decades ago as Tanaka showed that treatment with a vitamin D analogue, improved survival in leukemic mice [32]. Muto demonstrated that calcitriol can inhibit cell cycle and induces differentiation of leukaemia cells through VDR [152]. Other numerous studies on AML blasts or leukaemic cell lines showed that vitamin D induce cell differentiation and growth inhibition [30,31,141,145,153–155]. The exact mechanism by which the activation of the vitamin D receptor induces this effect is not completely clear and investigations have revealed complex cross-signals involving P13 kinase, MAPK pathway and probably the upregulation of factors such as p53 [131].

Unfortunately, early preclinical trials using supraphysiological doses that induced differentiation also induced hypercalcaemia [136,156]. However, other studies showed that fractionated doses could achieve the same effect on differentiation, maintaining the level of vitamin D in the physiological range [137].

There are several studies in which vitamin D therapy has been used as the single agent in myelodysplastic syndromes (MDS). The first study was carried out in 1985 by Koeffler and colleagues, reporting 18 patients treated with 1,25(OH)$_2$D$_3$ with a dose greater than 2 mg/day. Although 8 patients presented minor haematological responses, the response did not persist for more than 12 weeks and hypercalcaemia was a common toxicity [156].
In a retrospective study conducted by Hermine et al. [157], it was shown that VDR expression in AML is correlated to prognosis. Accordingly, patients presenting higher VDR expression have an increased survival. Moreover, patients’ prognosis is correlated to the expression of VDR-targeted genes. Patients with higher CAMP expression presented an increased event free survival (EFS) compared to patients with lower levels of CAMP expression.

Other studies with vitamin D analogues failed to demonstrate haematological responses in MDS although tolerance was adequate [158]. Recently, Motomura et al. randomized a series of 30 patients to receive 25(OH)D3 versus supportive treatment. Only one of the 15 patients in the vitamin D group progressed to AML versus seven in the control group [159].

There are several attempts to combine vitamin D with other cytotoxic agents. Siitonen et al. reported a series of 19 patients with MDSs treated with a combination of 13-cis retinoic acid, 1,25(OH)_{2}D_{3} (1 mg/day) and valproic acid, used as a histone deacetylase inhibitor [160]. Three patients had haematological response but intolerance was recorded in eight patients, due to 13-cis retinoic acid and valproic acid.

In 2008, a study was conducted with 63 patients with MDS with a combination of erythropoietin, 13-cis retinoic acid, 1,25(OH)_{2}D_{3} and thioguanine in the presence of blasts. An overall erythroid response of 60% was obtained, reaching 93% in low risk patients [161]. Subsequently, vitamin D analogues were combined with cytotoxic chemotherapy in a series of 53 patients with MDS in whom 13-cis retinoic acid (20–40 mg daily) was added to 1,25(OH)_{2}D_{3} (1–1.5 mg daily) with or without thioguanine. The overall response rate was 60% and 50% of patients achieved transfusional independence [162].

The only study that used vitamin D monotherapy in AML was conducted in the eighties on 5 patients, four of whom presented a transient reduction in the number of blasts and only one described a brief normalization of the spinal study [163]. In 1992, Slapak et al. reported the use of continuous infusion of cytarabine for 21 days (20 mg/m^2 daily), hydroxyurea (500 mg twice daily) and 1,25(OH)_{2}D_{3} (0.5 mg twice a day) [162]. An overall response rate of 79% was obtained with 45% complete response rate. The toxicity was primarily haematological consisting of neutropenia and thrombocytopenia, only two patients developed asymptomatic hypercalcemia that did not require treatment. These results were considered at least not inferior to those achieved with cytarabine as the sole agent. Ferrero and colleagues carried out another study in 2008 with a similar population of 30 patients (24 AML, 6 MDS) in which they used subcutaneous cytarabine (8 mg/m^2 twice a day), 1,25(OH)_{2}D_{3} (1 mg daily), 13-cis retinoic acid (20–40 mg daily) and thioguanine (40 mg daily). The median survival was 7.5 months, being 16 months for the responders. The toxicity was mainly related to cytopenias [164].

The only study published in the literature comparing combination treatment with vitamin D analogues (1,25(OH)_{2}D_{3} 1 \mu g/day) and chemotherapy (cytarabine 15 mg/m^{2} daily subcutaneously until the blasts were lower 50%) compared to a control group was performed in Sweden on a total of 78 patients, 68 with MDS and 15 with AML. Half of the patients also received 13-cis retinoic acid (1 mg/kg daily). The mean survival was 10.5 months, with no significant difference between both groups [165].

Interestingly, vitamin D serum levels have also been correlated to response rate to 5-azacytidine (AZA) among patients with MDS or AML. In this regard, Radujkovic et al. analysed serum levels before starting AZA in 58 patients. Estimated probability of 2-year overall survival in the low versus high vitamin D levels group was 14% versus 40% (p < 0.05). In multivariable analysis, adverse cytogenetics and vitamin D levels were independent predictors of survival [166]. Similarly, Lee et al. reported a series of 97 patients diagnosed with AML who received intensive chemotherapy; in this study, a significantly worse outcome was observed among those patients with low vitamin D levels [167]. These data are in contrast to those reported by Pardanani et al. who did not find any relationship between vitamin D levels and prognosis in a series of 409 patients diagnosed with different myeloid neoplasms and MDS [168].
There are also studies evaluating the role of vitamin D in lymphoid malignancies. In this regard, several preclinical studies have demonstrated activity of the vitamin D analogue EB1089 in the multiple myeloma cell line H929. This agent promotes apoptosis and induce cell cycle arrest by downregulation of cyclin-dependent kinases [169–171]. There are preclinical studies that show that vitamin D has an inhibitory effect on neoplastic lymphoid cells but to date there have been no studies in humans [172].

A retrospective study performed by Kelly J et al. analysed 183 patients who were enrolled in three SWOG trials and had 25(OH)D serum levels available. There was no association between vitamin D deficiency and clinical response. After a median follow-up of 5.4 years, vitamin D-deficient patients had a significantly worse progression free survival (PFS) (hazard ratio (HR), 2.00; \( p = 0.011 \)) and overall survival (OS) (HR, 3.57; \( p = 0.003 \)) as compared with those with higher levels. Multivariable analysis suggested that lower levels of vitamin D were associated with a higher risk of either progression or death but neither result was significant. In addition, 240 patients enrolled onto the parent PRIMA clinical trial were analysed. After a median follow-up of 6.6 years, vitamin D-deficient patients had significantly lower PFS (HR, 1.66; \( p = 0.013 \)) but not OS (HR, 1.84; \( p = 0.14 \)) as compared with those with higher levels Multivariable analysis confirmed that lower levels of vitamin D were associated with a higher risk of either progression or death [173].

Similar results have been reported by Tracy SI et al. in a series of 642 patients with follicular lymphoma. The authors evaluated whether vitamin D insufficiency was associated with adverse outcomes; with a median follow-up of 59 months, 297 patients (46%) had an event (progression, treatment failure), 78 had died and 42 (6.5%) had a lymphoma-related death. Vitamin D deficiency was associated with inferior EFS at 12 months (OR = 2.05; 95% confidence interval (CI) 1.18–3.54), OS (hazards ratio (HR) = 2.35; 95% CI 1.37–4.02) and lymphoma-specific survival (HR = 2.97; 95% CI 1.52–5.80) for the full cohort [174].

In diffuse large cell lymphoma Hohaus et al. analysed 128 patients. 25(OH)D levels below 20 ng/mL at diagnosis and IPI were independently associated with a worse EFS. Moreover, patients with normalized 25(OH)D levels following supplementation showed a better EFS as compared to those patients with persistent insufficient 25(OH)D levels [175].

4.2. Vitamin D as a Modulator of the Immune Response in Allogeneic Transplantation

There is considerable interest in vitamin D analogues for their immunomodulatory effects, which could be considered an effective approach among patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) to prevent graft-versus-host disease (GVHD). The VDR genes are polymorphic in the human population and this genetic variation in VDR has been investigated in patients undergoing HSCT. Cho and colleagues conducted an analysis of 147 patients. They analysed the polymorphisms for VDR and evaluated the association with the prognosis of the patients. They showed a correlation between the polymorphisms of the anchor site of the restriction enzyme Taq1 and survival, so that heterozygotes (who have at least one copy of the C allele) had a better overall and disease-free survival than homozygous TT. The functional significance of this allelic variation is unknown and no direct association with a higher or lower VDR activity was reported. This study also found that recipients with two copies for the “A” allele, related to polymorphisms for the Apal anchor site, had a lower risk of acute GVHD and infections [176]. These polymorphisms have been related to VDR activity so that homozygosity for the “a” allele translates into greater activity [177].

Middleton and colleagues studied a cohort of 88 patients with myeloid malignancies undergoing HSCT, correlating VDR polymorphisms of both recipients and donors with prognosis [178]. Like Cho et al., they detected a marked trend towards a decreased risk of acute GVHD in recipients with AA genotype (low VDR activity). Receptors with aa genotype and high VDR activity showed a trend toward a higher risk of acute GVHD, although differences were not statistically significant. However, recipients of donors with low VDR activity (AA) had a higher risk of death.

Bogunia-Kubik et al. published an analysis on 123 patients [177]. They found an association between the FokI FF genotype, which is associated with increased VDR activity and patient’s prognosis.
If the donor and the recipient had the FF genotype, the recipients had a higher risk of GVHD. The Apal genotype, as in other studies, also had an impact on the risk of GVHD. Contrary to the data described in the study by Middleton et al., the AA donor genotype (low VDR activity) was associated with a higher risk of GVHD as compared to the genotype that had at least one an allele. At the same time, aa receptors (high VDR activity) had a higher risk of death and GVHD compared to the genotype with low VDR activity, which is consistent with other studies.

Thus, the vitamin D receptor and its mediation on immune signalling appear to have an impact on immune reconstitution after HSCT and the risk of infection and graft versus host disease.

Remarkably, a significant proportion of patients display low levels of vit D before HSCT [179,180]. In this regard, several studies have been reported describing the impact of the vitamin D levels before HSCT and post-transplant outcomes. More specifically, von Bahr et al. described an association between low levels of vit D and an increased risk of GVHD and CMV reactivation [180]. Similar results have been described by Hansson et al., who described an increased risk of death, relapse and cGVHD among patients with low vit D levels although, strikingly, grades 2 to 4 aGVHD occurred more frequently among patients with normal levels of Vitamin D [181]. Moreover, a higher risk of relapse has also been described among patients with low vitamin D levels. In this regard, Radujkovic et al. analysed a series of 492 patients undergoing HSCT; results were validated in an independent cohort of 398 patients. 396 (80%) and 348 (87%) patients had vit D deficiency before transplant in the training and validation cohort, respectively. Vit D deficiency was significantly associated with inferior overall survival, which was mainly attributed to a higher risk of relapse (HR, 1.96; \( p = 0.006 \)) in patients diagnosed with myeloid (HR, 2.55; \( p = 0.014 \)) but not with lymphoid malignancies (HR, 1.60; \( p = 0.147 \)) [166].

With these data in mind we designed a phase I/II prospective trial in which 150 patients were included in three consecutive cohorts of 50 patients each group: control group (who did not receive vitamin D); low dose group (1000 UI vitamin D daily) and high dose group (5000 UI vitamin D daily). No significant differences were observed in terms of acute GVHD, relapse, non-relapse mortality and overall survival. By contrast, a significantly lower cumulative incidence of both overall and moderate plus severe chronic GVHD at 1 year was observed in patients receiving low (37.5% and 19.5%, respectively) or high doses of vitamin D (42.4% and 27%, respectively) as compared to the control group (67.5% and 44.7%, respectively) (\( p < 0.05 \)). In multivariable analysis, treatment with vitamin D significantly decreased the risk of both overall (for low dose (HR = 0.31, \( p = 0.002 \)) and for high dose of vitamin D (HR = 0.36, \( p = 0.006 \))) and moderate plus severe cGVHD (for low dose (HR = 0.22, \( p = 0.001 \)) and for high dose vitamin D (HR = 0.33, \( p = 0.01 \))). There were no adverse events attributed to the vitamin D, more specifically, no case of hypercalcemia was observed. With this low toxicity profile, a prospective randomized trial would be required to confirm the potential efficacy of vitamin D as immune-modulatory agent after HSCT [182].

5. Conclusions

Our knowledge of vitamin D effects has grown in the past 20 years. The mechanisms of action and the role of vitamin D receptor in addition to its classic effects on calcium and bone homeostasis is well stablished. Vitamin D receptor is expressed on immune cells, which are all capable of synthesizing the active vitamin D metabolite. Moreover, vitamin D has the capability to act in an autocrine manner and can modulate the innate and adaptive immune responses.

As far as the clinical applications of vitamin D is concerned, several studies have been reported both in myeloid as well as in lymphoid malignancies suggesting that vitamin D may promote tumour cells differentiation and might play a role, in combination with other agents, for the treatment of these disorders, although no prospective randomized study is available to confirm these findings. In addition, in the transplant setting, the effect of vitamin D on the immune system might also influence patient’s outcome and, in this regard, different studies have evaluated the relationship between vitamin D levels pre-HSCT and risk of infections, graft-versus-host disease and relapse after transplantation.
A phase I/II prospective trial suggests the potential benefit of the use of vitamin D to prevent GvHD. Prospective randomized trials would be required to confirm these findings.

Author Contributions: Writing-Original Draft Preparation, I.M., J.A.P.-S., M.M., E.C.-C.; Writing-Review & Editing, J.A.P.-S., M.M.; Supervision, J.A.P.-S.; Project Administration, M.M.; Funding Acquisition, J.A.P.-S.

Funding: This work was supported by research grants from ISCIII-FEDER (PI17/02177) M.M. has a predoctoral grant PFIS-ISCIII (FI16/00412).

Conflicts of Interest: The authors declare no conflict of interests.

Abbreviations
vit D Vitamin D
25(OH)D Calcidiol, 25 hydroxycholecalciferol or 25-hidroxivitamin D
1,25(OH)2D3 1,25-Dihydroxyvitamin D3
DBP Vitamin D-binding protein
CYP2R1 Vitamin D 25-hydroxylase or cytochrome P450 2R1
CYP27B1 1-α-Hydroxylase (1α-hydroxylase)
CYP24A1 Cytochrome P450 family 24 subfamily A member 1
FGF-23 Fibroblast growth factor 23
PTH Parathyroid hormone
TNFα Tumour necrosis factor α
IFNγ Interferon gamma
UV Ultra violet
VDR Vitamin D receptor
RXR Retinoid-X-receptor
VDRE Vitamin D responsive elements
HAT Histone acetyl transferases
NCoR Nuclear receptor corepressor
SMRT Retinoid or thyroid-hormone receptors
NFAT Nuclear factor of activated T-cells
TSH Thyroid-stimulating hormone
TRH Thyrotropin-releasing hormone
TLR Toll like receptor
NF-κB Nuclear factor κB
DC Dendritic cells
M-DCs Myeloid dendritic cells
P-DCs Plasmacytoid dendritic cells
MR Manose receptors
CAMP Cathelicidin
DEFB4 β defensin 2
CCR10 C-C chemokine receptor type 10
NOD2 Nucleotide-binding oligomerization domain-containing protein 2
SINE Introduction of a nuclear element
PAMPs Molecular patterns associated with pathogen surveillance
PRRs Pattern recognition receptors
MDR Multidrug resistance
HAMP Hepcidin antimicrobial peptide
CFU-GM Granulocyte macrophage colony forming cell
RAR Retinoic acid receptor
RXR Retinoid X receptor
SRC Steroid receptor coactivator
DRIP Vitamin D receptor interacting protein
PKC Protein kinase C
iNKT Invariant natural killer T cells
HSPC Hematopoietic stem progenitor cell
HSC Hematopoietic stem cell
MDS Myelodysplastic syndromes
AML Acute myeloblastic leukaemias
ATRA All-trans retinoic acid
APL Acute promyelocytic leukaemia
EFS Event free survival
AZA 5-Azacytidine
HR Hazard ratio
CI Confidence interval
OS Overall survival
HSCT Hematopoietic stem cell transplantation
CMV Cytomegalovirus
cGVHD Chronic graft-versus-host disease
aGVHD Acute graft-versus-host disease

References
1. Aranow, C. Vitamin D and the immune system. J. Investig. Med. 2011, 59, 881–886. [CrossRef] [PubMed]
2. Gil, A.; Plaza-Diaz, J.; Mesa, M.D. Vitamin D: Classic and novel actions. Ann. Nutr. Metab. 2018, 72, 87–95. [CrossRef] [PubMed]
3. Holick, M.F.; Richtand, N.M.; McNeill, S.C.; Holick, S.A.; Frommer, J.E.; Henley, J.W.; Potts, J.T.J. Isolation and identification of previtamin D3 from the skin of rats exposed to ultraviolet irradiation. Biochemistry 1979, 18, 1003–1008. [CrossRef] [PubMed]
4. Holick, M.F.; McLaughlin, J.A.; Clark, M.B.; Holick, S.A.; Potts, J.T.J.; Anderson, R.R.; Blank, I.H.; Parrish, J.A.; Elias, P. Photosynthesis of previtamin D3 in human and the physiologic consequences. Science 1980, 210, 203–205. [CrossRef] [PubMed]
5. Bell, N.H.; Greene, A.; Epstein, S.; Oexmann, M.J.; Shaw, S.; Shary, J. Evidence for alteration of the vitamin D endocrine system in blacks. J. Clin. Investig. 1985, 76, 470–473. [CrossRef] [PubMed]
6. Rachez, C.; Gamble, M.; Chang, C.P.; Atkins, G.B.; Lazar, M.A.; Freedman, L.P. The DRIP complex and SRC-1/p160 coactivators share similar nuclear receptor binding determinants but constitute functionally distinct complexes. Mol. Cell Biol. 2000, 20, 2718–2726. [CrossRef] [PubMed]
7. Seth-Vollenweider, T.; Joshi, S.; Dhawan, P.; Sif, S.; Christakos, S. Novel mechanism of negative regulation of 1,25-dihydroxyvitamin D3-induced 25-hydroxyvitamin D3 24-hydroxylase (Cyp24a1) transcription: Epigenetic modification involving cross-talk between protein-arginine methyltransferase 5 and the SWI/SNF complex. J. Biol. Chem. 2014, 289, 33958–33970. [CrossRef] [PubMed]
8. Perissi, V.; Jepsen, K.; Glass, C.K.; Rosenfeld, M.G. Deconstructing repression: Evolving models of co-repressor action. Nat. Rev. Genet. 2010, 11, 109–123. [CrossRef] [PubMed]
9. Horlein, A.J.; Naar, A.M.; Heinzel, T.; Torchia, J.; Gless, B.; Kurokawa, R.; Ryan, A.; Kamei, Y.; Söderström, M.; Glass, C.K.; et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995, 377, 397–404. [CrossRef] [PubMed]
10. Haussler, M.R.; Whitfield, G.K.; Kaneko, I.; Haussler, C.A.; Hsieh, D.; Hsieh, J.C.; Jurutka, P.W. Molecular mechanisms of vitamin D action. Calcif. Tissue Int. 2013, 92, 77–98. [CrossRef] [PubMed]
11. Van Etten, E.; Verlinden, L.; Giuliani, A.; Ramos-Lopez, E.; Branisteau, D.D.; Ferreira, G.B.; Overbergh, L.; Verstuyf, A.; Bouillon, R.; Roep, B.O.; et al. The vitamin D receptor gene FokI polymorphism: Functional impact on the immune system. Eur. J. Immunol. 2007, 37, 395–405. [CrossRef] [PubMed]
12. Harris, S.S.; Eccleshall, T.R.; Gross, C.; Dawson-Hughes, B.; Feldman, D. The vitamin D receptor start codon polymorphism (FokI) and bone mineral density in premenopausal American black and white women. J. Bone Miner. Res. 1997, 12, 1043–1048. [CrossRef] [PubMed]
13. Hewison, M. Vitamin D and the immune system: New perspectives on an old theme. Endocrinol. Metab. Clin. N. Am. 2010, 39, 365–379. [CrossRef] [PubMed]
14. Eisman, J.A.; Martin, T.J.; MacIntyre, I.; Moseley, J.M. 1,25-dihydroxyvitamin-D-receptor in breast cancer cells. Lancet 1979, 314, 1335–1336. [CrossRef]
15. Makishima, M.; Lu, T.T.; Xie, W.; Whitfield, G.K.; Domoto, H.; Evans, R.M.; Haussler, M.R.; Mangelsdorf, D.J. Vitamin D receptor as an intestinal bile acid sensor. *Science* **2002**, *296*, 1313–1316. [CrossRef] [PubMed]

16. Bouillon, R.; Carmeliet, G.; Verlinden, L.; Van Etten, E.; Verstuyf, A.; Luderer, H.F.; Lieben, L.; Mathieu, C.; Demay, M. Vitamin D and human health: Lessons from vitamin D receptor null mice. *Endocr. Rev.* **2008**, *29*, 726–776. [CrossRef] [PubMed]

17. Soory, K.; Schermerhorn, T.; Noda, M.; Surana, M.; Rhoten, W.B.; Meyer, M.; Fleischer, N.; Sharp, G.W.; Christakos, S. Calbindin-D(28k) controls [Ca(2+)](i) and insulin release. Evidence obtained from calbindin-d(28k) knockout mice and β cell lines. *J. Biol. Chem.* **1999**, *274*, 34343–34349. [CrossRef] [PubMed]

18. Tornquist, K. Pretreatment with 1,25-dihydroxycholecalciferol enhances thyrotropin-releasing hormone and inositol 1,4,5-trisphosphate-induced release of sequestered Ca(2+) in permeabilized GH4C1 pituitary cells. *Endocrinology* **1992**, *131*, 1677–1681. [CrossRef] [PubMed]

19. Herscovitch, K.; Dauletbaev, N.; Lands, L.C. Vitamin D as an anti-microbial and anti-inflammatory therapy for Cystic Fibrosis. *Paediatr. Respir. Rev.* **2013**, *15*, 154–162. [CrossRef] [PubMed]

20. Selles, J.; Boland, R. Rapid stimulation of calcium uptake and protein phosphorylation in isolated cardiac muscle by 1,25-dihydroxyvitamin D3. *Mol. Cell Endocrinol.* **1991**, *77*, 67–73. [CrossRef]

21. Girgis, C.M.; Clifton-Bligh, R.J.; Hamrick, M.W.; Holick, M.F.; Gunton, J.E. The roles of vitamin D in skeletal muscle: Form, function, and metabolism. *Endocr. Rev.* **2013**, *34*, 33–83. [CrossRef] [PubMed]

22. Boland, R. Role of vitamin D in skeletal muscle function. *Endocr. Rev.* **1986**, *7*, 434–448. [CrossRef] [PubMed]

23. Abe, E.; Miyaura, C.; Tanaka, H.; Shiina, Y.; Kuribayashi, T.; Suda, S.; Nishii, Y.; DeLuca, H.F.; Suda, T. 1α,25-dihydroxyvitamin D3 promotes fusion of mouse alveolar macrophages both by a direct mechanism and by a spleen cell-mediated indirect mechanism. *Proc. Natl. Acad. Sci. USA* **1983**, *80*, 5583–5587. [CrossRef] [PubMed]

24. Bhalla, A.K.; Amento, E.P.; Serog, B.; Glimcher, L.H. 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. *J. Immunol.* **1984**, *133*, 1748–1754. [PubMed]

25. Adams, J.S.; Gacad, M.A. Characterization of 1α-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. *J. Exp. Med.* **1985**, *161*, 755–765. [CrossRef] [PubMed]

26. Adams, J.S.; Sharma, O.P.; Gacad, M.A.; Singer, F.R. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. *J. Clin. Invest.* **1983**, *72*, 1856–1860. [CrossRef] [PubMed]

27. Barbour, G.L.; Coburn, J.W.; Slatopolsky, E.; Norman, A.W.; Horst, R.L. Hypercalcemia in an anephric patient with sarcoidosis: Evidence for extrarenal generation of 1,25-dihydroxyvitamin D. *N. Engl. J. Med.* **1981**, *305*, 440–443. [CrossRef] [PubMed]

28. Hewison, M. Vitamin D and the immune system. *J. Endocrinol.* **1992**, *132*, 173–175. [CrossRef] [PubMed]

29. Hewison, M.; Burke, F.; Evans, K.N.; Lammens, D.A.; Sansom, D.M.; Liu, P.; Modlin, R.L.; Adams, J.S. Extra-renal 25-hydroxyvitamin D3-1α-hydroxylase in human health and disease. *J. Steroid Biochem. Mol. Biol.* **2007**, *103*, 316–321. [CrossRef] [PubMed]

30. Abe, E.; Miyaura, C.; Sakagami, H.; Takeda, M.; Konno, K.; Yamazaki, T.; Yoshiki, S.; Suda, T. Differentiation of mouse myeloid leukemia cells induced by 1α,25-dihydroxyvitamin D3. *Proc. Natl. Acad. Sci. USA* **1981**, *78*, 4990–4994. [CrossRef] [PubMed]

31. Koeffler, H.P.; Amatruda, T.; Ikekawa, N.; Kobayashi, Y.; DeLuca, H.F. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues. *Cancer Res.* **1984**, *44*, 5624–5628. [PubMed]

32. Tanaka, H.; Abe, E.; Miyaura, C.; Shiina, Y.; Suda, T. 1α,25-dihydroxyvitamin D3 induces differentiation of human promyelocytic leukemia cells (HL-60) into monocyte-macrophages, but not into granulocytes. *Biochem. Biophys. Res. Commun.* **1983**, *117*, 86–92. [CrossRef]

33. Koeffler, H.P.; Reichel, H.; Bishop, J.E.; Norman, A.W. Gamma-Interferon stimulates production of 1,25-dihydroxyvitamin D3 by normal human macrophages. *Biochem. Biophys. Res. Commun.* **1985**, *127*, 596–603. [CrossRef]

34. Kreutz, M.; Andreesen, R.; Krause, S.W.; Szabo, A.; Ritz, E.; Reichel, H. 1,25-dihydroxyvitamin D3 production and vitamin D3 receptor expression are developmentally regulated during differentiation of human monocytes into macrophages. *Blood* **1993**, *82*, 1300–1307. [PubMed]

35. Liu, P.T.; Stenger, S.; Li, H.; Wenzel, L.; Tan, B.H.; Krutzik, S.R.; Ochoa, M.T.; Schauber, J.; Wu, K.; Meinken, C. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science* **2006**, *311*, 1770–1773. [CrossRef] [PubMed]
36. Gombart, A.F.; Borregaard, N.; Koeffler, H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. *FASEB J.* 2005, 19, 1067–1077. [CrossRef] [PubMed]

37. Wang, T.T.; Nestel, F.P.; Bourdeau, V.; Nağai, Y.; Wang, Q.; Liao, J.; Tavares-Mendoza, L.; Lin, R.; Hanrahan, J.W.; Mader, S. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. *J. Immunol.* 2004, 173, 2909–2912. [CrossRef] [PubMed]

38. Krutzik, S.R.; Hewison, M.; Liu, P.T.; Robles, J.A.; Stenger, S.; Adams, J.S.; Modlin, R.L. IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. *J. Immunol.* 2008, 181, 7115–7120. [CrossRef] [PubMed]

39. Liu, N.; Kaplan, A.T.; Low, J.; Low, J.; Nguyen, L.; Liu, G.Y.; Equils, O.; Hewison, M. Vitamin D induces innate antibacterial responses in human trophoblasts via an intracrine pathway. *Biol. Reprod.* 2009, 80, 398–406. [CrossRef] [PubMed]

40. Ren, S.; Nguyen, L.; Wu, S.; Encinas, C.; Adams, J.S.; Hewison, M. Alternative splicing of vitamin D-24-hydroxylase: A novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. *J. Biol. Chem.* 2005, 280, 20604. [CrossRef] [PubMed]

41. Sadeghi, K.; Wessner, B.; Laggner, U.; Ploder, M.; Tamandl, D.; Friedl, J.; Zügel, U.; Steinmeyer, A.; Pollak, A.; Roth, E.; et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. *Eur. J. Immunol.* 2006, 36, 361. [CrossRef] [PubMed]

42. Liu, Y.J. IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. *Annu. Rev. Immunol.* 2005, 23, 275–306. [CrossRef] [PubMed]

43. Colonna, M.; Trinchieri, G.; Liu, Y.J. Plasmacytoid dendritic cells in immunity. *Nat. Immunol.* 2004, 5, 1219–1226. [CrossRef] [PubMed]

44. Mahnke, K.; Johfhnson, T.S.; Ring, S.; Enk, A.H. Tolerogenic dendritic cells and regulatory T cells: A two-way relationship. *J. Dermatol. Sci.* 2007, 46, 159–167. [CrossRef] [PubMed]

45. Brennan, A.; Katz, D.R.; Nunn, J.D.; Barker, S.; Hewison, M.; Fraher, L.J.; O’Riordan, J.I. Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. *J. Immunol.* 1987, 61, 457–461. [PubMed]

46. Gauzzi, M.C.; Purificato, C.; Donato, K.; Jin, Y.; Wang, L.; Daniel, K.C.; Maghazachi, A.A.; Belardelli, F.; Adorini, L.; Gessani, S. Suppressive effect of 1α,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: Impairment of functional activities and chemotaxis. *J. Immunol.* 2005, 174, 270–276. [CrossRef] [PubMed]

47. Penna, G.; Adorini, L. 1α,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. *J. Immunol.* 2000, 164, 2405–2411. [CrossRef] [PubMed]

48. Griffin, M.D.; Lutz, W.H.; Phan, V.A.; Bachman, L.A.; McKean, D.J.; Kumar, R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. *Biochem. Biophys. Res. Commun.* 2000, 270, 701–708. [CrossRef] [PubMed]

49. Gregori, S.; Casorati, M.; Amuchastegui, S.; Smiroldo, S.; Davalli, A.M.; Adorini, L. Regulatory T cells induced by 1α,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. *J. Immunol.* 2001, 167, 1945–1953. [CrossRef] [PubMed]

50. Barrat, F.J.; Cua, D.J.; Boonstra, A.; Richards, D.F.; Crain, C.; Savelkoul, H.F.; de Waal-Malefyt, R.; Coffman, R.L.; Hawrylowicz, C.M.; O’Garra, A. In vitro generation of IL-10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by Th1- and Th2-inducing cytokines. *J. Exp. Med.* 2002, 195, 603–616. [CrossRef] [PubMed]

51. Steinman, R.M.; Hawiger, D.; Nussenweg, M.C. Tolerogenic dendritic cells. *Annu. Rev. Immunol.* 2003, 21, 685–711. [CrossRef] [PubMed]

52. Lemire, J.M.; Archer, D.C.; Beck, L.; Spiegelberg, H.L. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: Preferential inhibition of Th1 functions. *J. Nutr.* 1995, 125, 1704S–1708S. [CrossRef] [PubMed]
54. Boonstra, A.; Barrat, F.J.; Crain, C.; Heath, V.L.; Savelkoul, H.F.; O’Garra, A. 1α,25-Dihydroxyvitamin D3 has a direct effect on naïve CD4(+) T cells to enhance the development of Th2 cells. J. Immunol. 2001, 167, 4974–4980. [CrossRef] [PubMed]
55. Overbergh, L.; Decallonne, B.; Waer, M.; Rutgeerts, O.; Valckx, D.; Casteels, K.M.; Laureys, J.; Bouillon, R.; Mathieu, C. 1α,25-dihydroxyvitamin D3 induces an autoantigenspecific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524–543). Diabetes 2000, 49, 1301–1307. [CrossRef] [PubMed]
56. O’Kelly, J.; Hisatake, J.; Hisatake, Y.; Bishop, J.; Norman, A.; Koeffler, H.P. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J. Clin. Investig. 2002, 109, 1091–1099. [CrossRef] [PubMed]
57. Gregori, S.; Giarratana, N.; Smiroldo, S.; Uskokovic, M.; Adorini, L. A 1α,25-dihydroxyvitamin D (3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002, 51, 1367–1374. [CrossRef] [PubMed]
58. Weaver, C.T.; Hatton, R.D.; Mangan, P.R.; Harrington, L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 2007, 25, 821–852. [CrossRef] [PubMed]
59. Daniel, C.; Sartory, N.A.; Zahn, N.; Radeke, H.H.; Stein, J.M. Immune modulatory treatment of TNBS colitis with calcitriol is associated with a change of a Th1/Th17 to a Th2 and regulatory T cell profile. J. Pharmacol. Exp. Thor. 2008, 324, 23–33. [CrossRef] [PubMed]
60. Liu, N.; Nguyen, L.; Chun, R.F.; Lagishetty, V.; Ren, S.; Wu, S.; Hollis, B.; DeLuca, H.F.; Adams, J.S.; Hewison, M. Altered endocrine and autocrine metabolism of vitamin D in amouse model of gastrointestinal inflammation. Endocrinology 2008, 149, 4799–4808. [CrossRef] [PubMed]
61. Adorini, L.; Penna, G.; Giarratana, N.; Roncari, A.; Amuchastegui, S.; Daniel, K.C.; Uskokovic, M. Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands. J. Steroid Biochem. Mol. Biol. 2004, 89–90, 437–441. [CrossRef] [PubMed]
62. Dong, X.; Bachman, L.A.; Kumar, R.; Griffin, M.D. Generation of antigen-specific, interleukin-10-producing T cells using dendritic cell stimulation and steroid hormone conditioning. Transpl. Immunol. 2003, 11, 323–333. [CrossRef] [PubMed]
63. Provvedini, D.M.; Manolagas, S.C. 1α,25-dihydroxyvitamin D3 receptor distribution and effects in subpopulations of normal human T lymphocytes. J. Clin. Endocrinol. Metab. 1989, 68, 774–779. [CrossRef] [PubMed]
64. Urry, Z.; Xystrakis, E.; Richards, D.F.; McDonald, J.; Sattar, Z.; Cousins, D.J.; Corrigan, C.J.; Hickman, E.; Brown, Z.; Hawrylowicz, C.M. Ligation of TLR9 induced on human IL-10-secreting Tregs by 1α,25-dihydroxyvitamin D3 abrogates regulatory function. J. Clin. Investig. 2009, 119, 387–398. [CrossRef] [PubMed]
65. Nunn, J.D.; Katz, D.R.; Barker, S.; Fraher, L.J.; Hewison, M.; Hendy, G.N.; O’Riordan, J.L. Regulation of human tonsillar T-cell proliferation by the active metabolite of vitamin D3. Immunology 1986, 59, 479–484. [PubMed]
66. Veldman, C.M.; Cantorna, M.T.; DeLuca, H.F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 2000, 374, 334–338. [CrossRef] [PubMed]
67. Willheim, M.; Thien, R.; Schratbauer, K.; Bajna, E.; Holub, M.; Gruber, R.; Baier, K.; Pietschmann, P.; Reinisch, W.; Scheiner, O.; et al. Regulatory effects of 1α,25-dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocytes. J. Clin. Endocrinol. Metab. 1999, 84, 3739–3744. [CrossRef] [PubMed]
68. Iho, S.; Iwamoto, K.; Kura, F.; Okuno, Y.; Takahashi, T.; Hoshino, T. Mechanism in 1,25(OH)2D3-induced suppression of helper/suppressor function of CD4/CD8 cells to immunoglobulin production in B cells. Cell Immunol. 1990, 127, 12–25. [CrossRef] [PubMed]
69. Mathieu, C.; DeLuca, H.F. CD8(+) T cells are not necessary for 1α,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Proc. Natl. Acad. Sci. USA 2002, 99, 5557–5560. [CrossRef] [PubMed]
70. Topilski, I.; Flahson, L.; Naveh, Y.; Harmelin, A.; Levo, Y.; Shachar, I. The anti-inflammatory effects of 1,25-dihydroxyvitamin D3 on Th2 cells in vivo are due in part to the control of integrin-mediated T lymphocyte homing. Eur. J. Immunol. 2004, 34, 1068–1076. [CrossRef] [PubMed]
72. Sigmundsdottir, H.; Pan, J.; Debes, G.F.; Alt, C.; Habtezion, A.; Soler, D.; Butcher, E.C. DCs metabolize sunlight-induced vitamin D3 to “program” T cell attraction to the epidermal chemokine CCL27. *Nat. Immunol.* 2007, 8, 285–293. [CrossRef] [PubMed]

73. Yu, S.; Bruce, D.; Froicu, M.; Weaver, V.; Cantorna, M.T. Failure of T cell homing, reduced CD4/CD8αα intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. *Proc. Natl. Acad. Sci. USA* 2008, 105, 20834–20839. [CrossRef] [PubMed]

74. Rolf, L.; Muris, H.A.; Hupperts, R.; Damoiseaux, J. Vitamin D effects on B cell function in autoimmunity. *Ann. N.Y. Acad. Sci.* 2014, 1317, 84–91. [CrossRef] [PubMed]

75. Baumgarth, N. The double life of a B-1 cell: Selfreactivity selects for protective effector functions. *Nat. Rev. Immunol.* 2011, 11, 34–46. [CrossRef] [PubMed]

76. Van Leeuwen, M.; Damoiseaux, J.; Duijvestijn, A.; Tervaert, J.W. The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis. *Autoimmun. Rev.* 2009, 9, 53–57. [CrossRef] [PubMed]

77. Kalampokis, I.; Yoshizaki, A.; Tedder, T.F. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. *Arthritis Res. Ther.* 2013, 15, S1. [CrossRef] [PubMed]

78. Mauri, C.; Bosma, A. Immune regulatory function of B cells. *Annu. Rev. Immunol.* 2012, 30, 221–241. [CrossRef] [PubMed]

79. Fillatreau, S.; Sweenie, C.H.; McGeachy, M.J.; Gray, D.; Anderton, S.M. B cells regulate autoimmunity by provision of IL-10. *Nat. Rev. Immunol.* 2002, 3, 944–950. [CrossRef] [PubMed]

80. Mauri, C.; Gray, D.; Mushtaq, N.; Londei, M. Prevention of arthritis by interleukin 10-producing B cells. *J. Exp. Med.* 2003, 197, 489–501. [CrossRef] [PubMed]

81. Sun, J.B.; Flach, C.F.; Czerkinsky, C.; Holmgren, J. B lymphocytes promote expansion of regulatory T cells in oral tolerance: Powerful induction by antigen coupled to cholera toxin B subunit. *J. Immunol.* 2008, 181, 8278–8287. [CrossRef] [PubMed]

82. Blair, P.A.; Noreña, L.Y.; Flores-Borja, F.; Rawlings, D.J.; Isenberg, D.A.; Ehrenstein, M.R.; Mauri, C. CD19+ CD24(hi) CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. *Immunity* 2010, 32, 129–140. [CrossRef] [PubMed]

83. Duddy, M.; Niino, M.; Adatia, F.; Hebert, S.; Freedman, M.; Atkins, H.; Kim, H.J.; Bar-Or, A. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. *J. Immunol.* 2007, 178, 6092–6099. [CrossRef] [PubMed]

84. Knippenberg, S.; Peelen, E.; Smolders, J.; Thewissen, M.; Menheere, P.; Tervaert, J.W.; Hupperts, R.; Damoiseaux, J. Reduction in IL-10 producing B cells (B reg) in multiple sclerosis is accompanied by a reduced naïve/memory B reg ratio during a relapse but not in remission. *J. Neuroimmunol.* 2011, 239, 80–86. [CrossRef] [PubMed]

85. Kalampokis, I.; Yoshizaki, A.; Tedder, T.F. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. *Arthritis Res. Ther.* 2013, 15, S1. [CrossRef] [PubMed]

86. Chen, S.; Sims, G.P.; Chen, X.X.; Gu, Y.Y.; Chen, S.; Lipsky, P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. *J. Immunol.* 2007, 179, 1634–1647. [CrossRef] [PubMed]

87. Morgan, J.W.; Koutroubou, N.; Ford, D.; Maizel, A.L. Vitamin D-mediated gene regulation in phenotypically defined human B cell subpopulations. *Endocrinology* 2000, 141, 3225–3234. [CrossRef] [PubMed]

88. Heine, G.; Niesner, U.; Chang, H.D.; Steinmeyer, A.; Zügel, U.; Zuberbier, T.; Radbruch, A.; Worm, M. 1,25-dihydroxyvitamin D(3) promotes IL-10 production in human B cells. *Eur. J. Immunol.* 2000, 30, 2210–2218. [CrossRef] [PubMed]

89. Lugar, P.L.; Love, C.; Grammer, A.C.; Dave, S.S.; Lipsky, P.E. Molecular characterization of circulating plasma cells in patients with active systemic lupus erythematosus. *PLoS ONE* 2012, 7, e44362. [CrossRef] [PubMed]

90. Lemire, J.M.; Adams, J.S.; Sakai, R.; Jordan, S.C. 1α,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. *J. Clin. Investig.* 1984, 74, 657–661. [CrossRef] [PubMed]

91. Chen, W.C.; Vayuvegula, B.; Gupta, S. 1,25-Dihydroxyvitamin D3-mediated inhibition of human B cell differentiation. *Clin. Exp. Immunol.* 1987, 69, 639–646. [PubMed]

92. Provedini, D.M.; Tsoukas, C.D.; Deftos, L.J.; Manolagas, S.C. 1α,25- Dihydroxyvitamin D3-binding macromolecules in human B lymphocytes: Effects on immunoglobulin production. *J. Immunol.* 1986, 136, 2734–2740.
93. Iho, S.; Takahashi, T.; Kura, F.; Sugiyama, H.; Hoshino, T. The effect of 1,25-dihydroxyvitamin D3 on in vitro immunoglobulin production in human B cells. *J. Immunol.* 1986, 136, 4427–4431. [PubMed]

94. Hartmann, B.; Heine, G.; Babina, M.; Steinmeyer, A.; Zügel, U.; Radbruch, A.; Worm, M. Targeting the vitamin D receptor inhibits the B cell-dependent allergic immune response. *Allergy* 2011, 66, 540–548. [CrossRef] [PubMed]

95. Heine, G.; Anton, K.; Henz, B.M.; Worm, M. 1α,25-dihydroxyvitamin D3 inhibits anti-CD40 plus IL-4-mediated IgE production in vitro. *Eur. J. Immunol.* 2002, 32, 3395–3404. [CrossRef]

96. Nashold, F.E.; Hoag, K.A.; Goverman, J.; Hayes, C.E. Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. *J. Neuroimmunol.* 2001, 119, 16–29. [CrossRef]

97. Spach, K.M.; Nashold, F.E.; Dittel, B.N.; Hayes, C.E. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. *J. Immunol.* 2006, 177, 6030–6037. [CrossRef]

98. Chun, R.F.; Liu, P.T.; Modlin, R.L.; Adams, J.S.; Hewison, M. Impact of vitamin D on immune function: Lessons learned from genome-wide analysis. *Front. Physiol.* 2014, 5, 151. [CrossRef] [PubMed]

99. Kallas, M.; Green, F.; Hewison, M.; White, C.; Kline, G. Rare causes of calcitriol-mediated hypercalcemia: A case report and literature review. *J. Clin. Endocrinol. Metab.* 2010, 95, 3111–3117. [CrossRef] [PubMed]

100. Reichel, H.; Koeffler, H.P.; Norman, A.W. Regulation of 25-hydroxyvitamin D3 metabolism in a human promyelocytic leukemia cell line (HL60): 1,25-dihydroxyvitamin D3 stimulates the synthesis of 24, 25-dihydroxyvitamin D3. *Arch. Biochem. Biophys.* 1986, 251, 222–231. [CrossRef]

101. Akutsu, N.; Lin, R.; Bastien, Y.; Bestawros, A.; Enepedikis, D.J.; Black, M.J.; White, J.H. Regulation of gene expression by 1α,25-dihydroxyvitamin D3 and its analog EB1089 undergrowth-inhibitory conditions in squamous carcinoma cells. *Mol. Endocrinol.* 2001, 15, 1127–1139. [CrossRef] [PubMed]

102. Lin, R.; Nagai, Y.; Sladek, R.; Bastien, Y.; Ho, J.; Petrecca, K.; Sotiropoulou, G.; Diamandis, E.P.; Hudson, T.J.; White, J.H. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. *Mol. Endocrinol.* 2002, 16, 1243–1256. [CrossRef] [PubMed]

103. Wang, T.T.; Tavera-Mendoza, L.E.; Laperriere, D.; Libby, E.; MacLeod, N.B.; Nagai, Y.; Bourdeau, V.; Konstorum, A.; Lallemant, B.; Zhang, R.; et al. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. *Mol. Endocrinol.* 2005, 19, 2685–2695. [CrossRef] [PubMed]

104. Liu, P.T.; Schenk, M.; Walker, V.P.; Dempsey, P.W.; Kanchanapoomi, M.; Wheelwright, M.; Vazirnia, A.; Zhang, X.; Steinmeyer, A.; Zügel, U.; et al. Convergence of IL-1β and VDR activation pathways in human TLR2/1-induced antimicrobial responses. *PLoS ONE* 2009, 4, e5810. [CrossRef] [PubMed]

105. Wang, T.T.; Dabbas, B.; Laperriere, D.; Bitton, A.J.; Soualhine, H.; Tavera-Mendoza, L.E.; Dionne, S.; Servant, M.J.; Bitton, A.; Seidman, E.G.; et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin β2 innate immune pathway defective in Crohn disease. *J. Biol. Chem.* 2010, 285, 22227–2231. [CrossRef] [PubMed]

106. Moresco, E.M.; LaVine, D.; Beutler, B. Toll-like receptors. *Curr. Biol.* 2011, 21, R488–R493. [CrossRef] [PubMed]

107. Bacchetta, J.Z.J.; Sea, J.L.; Sea, J.L.; Chun, R.F.; Lisse, T.S.; Zavala, K.; Nayak, A.; Wesseling-Perry, K.; Westerman, M.; Hollis, B.W.; et al. Suppression of iron-regulatory hepcidin by vitamin D. *J. Am. Soc. Nephrol.* 2014, 25, 564–572. [CrossRef] [PubMed]

108. Ganz, T. Iron in innate immunity: Starve the invaders. *Curr. Opin. Immunol.* 2009, 21, 63–67. [CrossRef] [PubMed]

109. Drakesmith, H.; Prentice, A.M. Hepcidin and the iron-infection axis. *Science* 2012, 338, 768–772. [CrossRef] [PubMed]

110. Kim, T.H.; Lee, B.; Kwon, E.; Choi, S.J.; Lee, Y.H.; Song, G.G.; Sohn, J.; Ji, J.D. Regulation of TREM-1 expression by 1,25-dihydroxyvitamin D3 in human monocytes/macrophages. *Immunol. Lett.* 2013, 154, 80–85. [CrossRef] [PubMed]

111. Fritsche, J.; Mondal, K.; Ehrenspurger, A.; Andreessen, R.; Kreutz, M. Regulation of 25-hydroxyvitamin D3-α-hydroxylase and production of 1α,25-dihydroxyvitamin D3 by human dendritic cells. *Blood* 2003, 102, 3314–3316. [CrossRef] [PubMed]
112. Hewison, M.; Freeman, L.; Hughes, S.V.; Evans, K.N.; Bland, R.; Eliopoulos, A.G.; Kilby, M.D.; Moss, P.A.; Chakraverty, R. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. *J. Immunol.* 2003, 170, 5382–5390. [CrossRef] [PubMed]

113. Ooi, J.H.; McDaniel, K.L.; Weaver, V.; Cantorna, M.T. Murine CD8+ T cells but not macrophages express the vitamin D1α-hydroxylase. *J. Nutr. Biochem.* 2014, 25, 58–65. [CrossRef] [PubMed]

114. Ustianowski, A.; Shaffer, R.; Collin, S.; Wilkinson, R.J.; Davidson, R.N. Prevalence and associations of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: A case-control study. *Lancet* 2000, 355, 618–621. [CrossRef]

115. Lauridsen, A.L.; Vestergaard, P.; Hermann, A.P.; Brot, C.; Heckendorff, L.; Mosekilde, L.; Nexo, E. Plasma vitamin D levels and vitamin D-binding protein concentration in foreign-born persons with tuberculosis in London. *J. Infect.* 2005, 50, 432–437. [CrossRef] [PubMed]

116. Williams, B.; Williams, A.J.; Anderson, S.T. Vitamin D deficiency and insufficiency in children with tuberculosis. *Pediatr. Infect. Dis. J.* 2008, 27, 941–942. [CrossRef] [PubMed]

117. Jeong, L.; Yamshchikov, A.V.; Judd, S.E.; Blumberg, H.M.; Martin, G.S.; Ziegler, T.R.; Tangpricha, V. Alterations in vitamin D status and antimicrobial peptide levels in patients in the intensive care unit with sepsis. *Epidemiol. Infect.* 2006, 134, 1129–1140. [CrossRef] [PubMed]

118. Coussens, A.K.; Wilkinson, R.J.; Hanifa, Y.; Nikolayevskyy, V.; Elkington, P.T.; Islam, K.; Timms, A.P.; Packe, G.E.; Moore-Gillon, J.C.; Davidson, R.N.; et al. High-dose vitamin D (3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: A double-blind randomised controlled trial. *Lancet* 2011, 377, 242–250. [CrossRef]

119. Martineau, A.R.; Timms, P.M.; Bothamley, G.H.; Hanifa, Y.; Islam, K.; Claxton, A.P.; Packe, G.E.; Moore-Gillon, J.C.; Davidson, R.N.; et al. Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis. *J. Immunol.* 2003, 170, 5382–5390. [CrossRef] [PubMed]

120. Hewison, M.; Freeman, L.; Hughes, S.V.; Evans, K.N.; Bland, R.; Eliopoulos, A.G.; Kilby, M.D.; Moss, P.A.; Chakraverty, R. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. *J. Immunol.* 2003, 170, 5382–5390. [CrossRef] [PubMed]

121. Packey, C.D.; Sartor, R.B. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. *Curr. Opin. Infect. Dis.* 2009, 22, 292–301. [CrossRef] [PubMed]

122. Cannell, J.J.; Vieth, R.; Umhau, J.C.; Holick, M.F.; Grant, W.B.; Madronich, S.; Garland, C.F.; Giovannucci, E. Epidemic influenza and vitamin D. *Epidemiol. Infect.* 2016, 134, 1129–1140. [CrossRef] [PubMed]

123. Lagishtety, V.; Misharin, A.V.; Liu, N.Q.; Lisse, I.M.; Andersen, P.L.; Glerup, H.; Sodemann, M.; Moukhtar, T.R.; Tangpricha, V. Alterations in vitamin D status and antimicrobial peptide levels in patients in the intensive care unit with sepsis. *J. Transl. Med.* 2009, 7, 28. [CrossRef] [PubMed]

124. Coulson, A.K.; Wilkinson, R.J.; Hanifa, Y.; Nikolayevskyy, V.; Elkington, P.T.; Islam, K.; Timms, A.P.; Packe, G.E.; et al. Vitamin D accelerates resolution of inflammatory responses involved in innate immunity. *Nat. Immunol.* 2003, 4, 269–273. [CrossRef] [PubMed]

125. Packey, C.D.; Sartor, R.B. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. *Curr. Opin. Infect. Dis.* 2009, 22, 292–301. [CrossRef] [PubMed]

126. Baehni, L.; Lichtner, P.; Chiacchiera, F.; Hirsch, C.; Hohlfeld, R. n-3 fatty acids and their metabolites are involved in innate immunity. *Nat. Immunol.* 2003, 4, 269–273. [CrossRef] [PubMed]

127. Lauridsen, A.L.; Vestergaard, P.; Hermann, A.P.; Brot, C.; Heckendorff, L.; Mosekilde, L.; Nexo, E. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): Across-sectional study on 595 early postmenopausal women. *Calcif. Tissue Int.* 2001, 68, 266–271. [PubMed]

128. Wang, T.J.; Zhang, F.; Richards, J.B.; Kestenbaum, B.; Van Meurs, J.B.; Berry, D.; Kiel, D.P.; Streeter, E.A.; Ohlsson, C.; Koller, D.L.; et al. Common genetic determinants of vitamin D insufficiency: A genome-wide association study. *Lancet* 2010, 376, 180–188. [CrossRef]

129. Chun, R.F.; Lauridsen, A.L.; Suon, L.; Zella, L.A.; Pike, J.W.; Modlin, R.L.; Martineau, A.R.; Wilkinson, R.J.; Adams, J.; Hewison, M. Vitamin D-binding protein directs monocyte responses to 25-hydroxy-and 1,25-dihydroxy vitamin D. *J. Clin. Endocrinol. Metab.* 2010, 95, 3368–3376. [CrossRef] [PubMed]
130. Chun, R.F.; Peercy, B.E.; Adams, J.S.; Hewison, M. Vitamin D binding protein and monocyte response to 25-hydroxy vitamin D and 1,25-dihydroxyvitamin D: Analysis by mathematical modeling. *PLoS ONE* **2012**, *7*, e30773. [CrossRef] [PubMed]

131. Kim, M.; Mirandola, L.; Pandey, A.; Nguyen, D.D.; Jenkins, M.R.; Turcel, M.; Cobos, E.; Chiriva-Internati, M. Application of vitamin D and derivatives in hematological malignancies. *Cancer Lett.* **2012**, *319*, 8–22. [CrossRef] [PubMed]

132. Miyaura, C.; Abe, E.; Kuribayashia, T.; Tanakaa, H.; Konno, K.; Nishii, Y.; Suda, T. 1α,25-dihydroxyvitamin D3 induced differentiation of human myeloid leukemia cells. *Biochem. Biophys. Res. Commun.* **1981**, *105*, 937–943. [CrossRef]

133. Choudhuri, U.; Adams, J.A.; Byrom, N.; McCarthy, D.M.; Barrett, J. 1,25-Dihydroxyvitamin D3 induces normal mononuclear blood cells to differentiate in the direction of monocyte-macrophages. *Haematologia (Budap)* **1990**, *23*, 9–19. [CrossRef] [PubMed]

134. Takahashi, T.; Suzuki, A.; Ichiba, S.; Okuno, Y.; Sugiyama, H.; Imura, H.; Nakamura, K.; Iho, S.; Hoshino, T. Effect of 1,25(OH)2D3 on normal human CFU-GM: Target cells of the agent in the suppression of colony formation and induction of macrophage colonies. *Int. J. Hematol.* **1991**, *54*, 57–63. [PubMed]

135. Hall, A.C.; Juckett, M.B. The Role of vitamin D in hematologic disease and stem cell transplantation. *Nutrients* **2013**, *5*, 2206–2221. [CrossRef] [PubMed]

136. Bunce, C.M.; Brown, G.; Hewison, M. Vitamin D and hematopoiesis. *Trends Endocrinol. Metab.* **1997**, *8*, 245–251. [CrossRef]

137. Grande, A.; Montanari, M.; Tagliafico, E.; Manfredini, R.; Zanocco Marani, T.; Siena, M.; Tenedini, E.; Gallinelli, A.; Ferrari, S. Physiological levels of 1α,25 dihydroxyvitamin D3 induce the monocytic commitment of CD34+ hematopoietic progenitors. *J. Leukoc. Biol.* **2002**, *71*, 641–651. [CrossRef] [PubMed]

138. Friedman, A.D. Transcriptional control of granulocyte and monocyte development. *Oncogene* **2007**, *26*, 6816–6828. [CrossRef] [PubMed]

139. Labrecque, J.; Allan, D.; Chambon, P.; Iscove, N.N.; Lohnes, D.; Hoang, T. Impaired granulocytic differentiation in vitro in hematopoietic cells lacking retinoic acid receptors α1 and gamma. *Blood* **1998**, *92*, 607–615. [PubMed]

140. Studzinski, G.P.; Harrison, J.S.; Wang, X.; Sarkar, S.; Danilenko, M. Vitamin D control of hematopoietic cell differentiation and leukemia. *J. Cell Biochem.* **2015**, *116*, 1500–1512. [CrossRef] [PubMed]

141. Hughes, P.J.; Marcinkowska, E.; Gocek, E.; Studzinski, G.P.; Brown, G. Vitamin D3-driven signals for myeloid cell differentiation-implications for differentiation therapy. *Leuk. Res.* **2010**, *34*, 553–565. [CrossRef] [PubMed]

142. Kharbanda, S.; Saleem, A.; Emoto, Y.; Stone, R.; Rapp, U.; Kufe, D. Activation of ras-1 and mitogen-activated protein kinases during monocytic differentiation of human myeloid leukemia cells. *J. Biol. Chem.* **1994**, *269*, 4070–4077. [PubMed]

143. Okazaki, T.; Bielawska, A.; Domae, N.; Bell, R.M.; Hannun, Y.A. Characteristics and partial purification of a novel cytosolic, magnesium-independent, neutral sphingomyelinase activated in the early signal transduction of 1α,25-dihydroxyvitamin D3-induced HL-60 cell differentiation. *J. Biol. Chem.* **1994**, *269*, 4070–4077. [PubMed]

144. Yu, S.; Cantorna, M.T. The vitamin D receptor is required for iNKT cell development. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 5207–5212. [CrossRef] [PubMed]

145. Weeres, M.A.; Robien, K.; Ahn, Y.O.; Neulen, M.L.; Bergerson, R.; Miller, J.S.; Verneris, M.R. The effects of 1,25-dihydroxyvitamin D3 on in vitro human NK cell development from hematopoietic stem cells. *J. Immunol.* **2014**, *193*, 3456–3462. [CrossRef] [PubMed]
149. Jeanson, N.T.; Scadden, D.T. Vitamin D receptor deletion leads to increased hematopoietic stem and progenitor cells residing in the spleen. Blood 2010, 116, 4126–4129. [CrossRef] [PubMed]

150. Cortes, M.; Chen, M.J.; Stachura, D.L.; Liu, S.Y.; Kwan, W.; Wright, F.; Vo, L.T.; Theodore, L.N.; Esain, V.; Frost, I.M.; et al. Developmental Vitamin D availability impacts hematopoietic stem cell production. Cell Rep. 2016, 17, 458–468. [CrossRef] [PubMed]

151. Cortes, M.; Liu, S.Y.; Kwan, W.; Alexa, K.; Goessling, W.; North, T.E. Accumulation of the vitamin D precursor cholecalciferol antagonizes hedgehog signaling to impair hemogenic endothelium formation. Stem Cell Rep. 2015, 5, 471–479. [CrossRef] [PubMed]

152. Muto, A.; Kizaki, M.; Yamato, K.; Kawai, Y.; Kamata-Matsushita, M.; Ueno, H.; Ohguchi, M.; Nishihara, T.; Koeffler, H.P.; Ikeda, Y. 1,25-dihydroxyvitamin D3 induces differentiation of a retinoic acid–resistant acute promyelocytic leukemia cell line (U937) associated with expression of p21 WAF1/CIP1 and p27 KIP1. Blood 1999, 93, 2225–2233. [PubMed]

153. Bastie, J.N.; Balitrand, N.; Guidez, F.; Guillemot, I.; Larghero, J.; Calabresse, C.; Chomienne, C.; Delva, L. 1α,25-dihydroxyvitamin D3 transrepresses retinoic acid transcriptional activity via vitamin D receptor in myeloid cells. Mol. Endocrinol. 2004, 18, 2685–2699. [CrossRef] [PubMed]

154. Ji, Y.; Studzinski, G.P. Retinoblastoma protein and CCAAT/enhancer-binding protein β are required for 1,25-dihydroxyvitamin D3-induced monocytic differentiation of HL60 cells. Cancer Res. 2004, 64, 370–377. [CrossRef] [PubMed]

155. Gemelli, C.; Orlandi, C.; Zanocco Marani, T.; Martello, A.; Vignudelli, T.; Ferrari, F.; Montanari, M.; Parenti, S.; Testa, A.; Grande, A.; et al. The vitamin D3/Hox-A10 pathway supports MafB function during the monocyte differentiation of human CD34+ hematopoietic progenitors. J. Immunol. 2008, 181, 5660–5672. [CrossRef] [PubMed]

156. Koeffler, H.P.; Hirji, K.; Itiri, L. 1,25-dihydroxyvitamin D3: In vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat. Rep. 1985, 69, 1399–1407. [PubMed]

157. Callens, C.; Coulon, S.; Naudin, J.; Radford-Weiss, I.; Boissel, N.; Raffoux, E.; Wang, P.H.; Agarwal, S.; Tamouza, H.; Paubelle, E.; et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J. Exp. Med. 2010, 207, 731–750. [CrossRef] [PubMed]

158. Molnar, I.; Stark, N.; Lovato, J.; Powell, B.L.; Cruz, J.; Hurd, D.D.; Mathieu, J.S.; Chen, T.C.; Holick, M.F.; Cambra, S.; et al. Treatment of low-risk myelodysplastic syndromes with high-dose daily oral cholecalciferol (2000–4000 IU vitamin D(3)). Leukemia 2007, 21, 1089–1092. [CrossRef] [PubMed]

159. Motomura, S.; Kanamori, H.; Maruta, A.; Kodama, F.; Ohkubo, T. The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am. J. Hematol. 1991, 38, 67–68. [CrossRef] [PubMed]

160. Siitonen, T.; Timonen, T.; Juvonen, E.; Terävä, V.; Kutila, A.; Honkanen, T.; Mikkola, M.; Hallman, H.; Kauppiä, M.; Nyländen, P.; et al. Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. Haematologica 2007, 92, 1119–1122. [CrossRef] [PubMed]

161. Ferrero, D.; Darbesio, A.; Giai, V.; Genuardi, M.; Dellacas, C.M.; Sorasio, R.; Bertini, M.; Boccardoro, M. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes. Br. J. Haematol. 2009, 144, 342–349. [CrossRef] [PubMed]

162. Slapak, C.A.; Desforges, J.F.; Fogaren, T.; Miller, K.B. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. Am. J. Hematol. 1992, 41, 178–183. [CrossRef] [PubMed]

163. Harrison, J.S.; Bershadsky, A. Clinical experience using vitamin D and analogs in the treatment of myelodysplasia and acute myeloid leukemia: A review of the literature. Leuk. Res. Treat. 2012, 2012, 125814. [CrossRef] [PubMed]

164. Ferrero, D.; Campa, E.; Dellacas, C.; Campana, S.; Foli, C.; Boccardoro, M. Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome. Haematologica 2004, 89, 619–620. [PubMed]
165. Hellström, E.; Robert, K.H.; Hellström, E.; Robert, K.H.; Samuelsson, J.; Lindemalm, C.; Grimfors, G.; Kimby, E.; Oberg, G.; Winquist, I.; et al. Treatment of myelodysplastic syndromes with retinoic acid and 1α-hydroxy-vitamin D3 in combination with low-dose ara-c is not superior to ara-c alone. Results from a randomized study. The scandinavian myelodysplasia group (SMG). Eur. J. Haematol. 1990, 45, 255–261. [CrossRef] [PubMed]

166. Radujkovic, A.; Schnitzler, P.; Ho, A.D.; Dreger, P.; Luft, T. Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia. Clin. Nutr. 2017, 36, 542–551. [CrossRef] [PubMed]

167. Lee, H.J.; Muindi, J.R.; Tan, W.; Hu, Q.; Wang, D.; Liu, S.; Wilding, G.E.; Ford, L.A.; Sait, S.N.; Block, A.W.; et al. Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia. Cancer 2014, 120, 521–529. [CrossRef] [PubMed]

168. Park, W.H.; Seol, J.G.; Kim, E.S.; Binderup, L.; Koeffler, H.P.; Kim, B.K.; Lee, Y.Y. The induction of apoptosis with induction of the cyclin-dependent kinase inhibitor p27. Exp. Cell Res. 2000, 254, 279–286. [CrossRef] [PubMed]

169. Tracy, S.I.; Maurer, M.J.; Witzig, T.E.; Drake, M.T.; Ansell, S.M.; Nowakowski, G.S.; Thompson, C.A.; Amiot, M. Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Blood 1996, 88, 4659–4666. [PubMed]

170. Pardanani, A.; Drake, M.T.; Finke, C.; Lasho, T.L.; Rozell, S.A.; Jimma, T.; Tefferi, A. Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: Clinical correlates and prognostic studies. Am. J. Hematol. 2011, 86, 1013–1016. [CrossRef] [PubMed]

171. Puthier, D.; Bataille, R.; Barillè, S.; Mellerin, M.P.; Harousseau, J.L.; Ponzio, A.; Robillard, N.; Wijdenes, J.; Amiot, M. Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Blood Cancer J. 2017, 7, e595. [CrossRef] [PubMed]

172. Luong, Q.T.; Koeffler, H.P. Vitamin D compounds in leukemia. J. Steroid Biochem. Mol. Biol. 2005, 97, 195–202. [CrossRef] [PubMed]

173. Kelly, J.L.; Salles, G.; Goldman, B.; Fisher, R.I.; Brice, P.; Press, O.; Casanovas, O.; Maloney, D.G.; Soubeyran, P.; Rimzsa, L.; et al. Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: A prospective evaluation in swog and lysa studies. J. Clin. Oncol. 2015, 33, 1482–1490. [CrossRef] [PubMed]

174. Tracy, S.I.; Maurer, M.J.; Witzig, T.E.; Drake, M.T.; Ansell, S.M.; Nowakowski, G.S.; Thompson, C.A.; Inwards, D.J.; Johnston, P.B.; Micallef, I.N.; et al. Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. Blood Cancer J. 2017, 7, e595. [CrossRef] [PubMed]

175. Hohaus, S.; Tisi, M.C.; Bellesi, S.; Maiolo, E.; Alma, E.; Tartaglia, G.; Corrente, F.; Cuccaro, A.; D’Alò, F.; Basile, U.; et al. Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. Cancer Med. 2018, 7, 270–281. [CrossRef] [PubMed]

176. Cho, H.J.; Shin, D.Y.; Kim, J.H.; Bae, J.Y.; Lee, K.H.; See, C.J.; Kim, N.; Park, E.K.; Ra, E.K.; Lee, J.E.; et al. Impact of vitamin D receptor gene polymorphisms on clinical outcomes of HLA-matched sibling hematopoietic stem cell transplantation. Clin. Transplant. 2012, 26, 476–483. [CrossRef] [PubMed]

177. Bogunia-Kubik, K.; Middleton, P.; Norden, J.; Dickinson, A.; Lange, A. Association of vitamin D receptor polymorphisms with the outcome of allogeneic haematopoietic stem cell transplantation. Int. J. Immunogenet. 2008, 35, 207–213. [CrossRef] [PubMed]

178. Middleton, P.G.; Cullup, H.; Dickinson, A.M.; Norden, J.; Jackson, G.H.; Taylor, P.R.; Cavet, J. Vitamin D receptor gene polymorphism associates with graft-versus-host disease and survival in HLA-matched sibling allogeneic bone marrow transplantation. Bone Marrow Transplant. 2002, 30, 223–228. [CrossRef] [PubMed]

179. Glotzbeker, B.; Ho, V.T.; Aldridge, J.; Kim, H.T.; Horowitz, G.; Ritz, J.; Soiffer, R.; Avigan, D.; Rosenblatt, J. Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT correlate with the development of chronic GvHD. Bone Marrow Transplant. 2013, 48, 593–597. [CrossRef] [PubMed]

180. Von Bahr, L.; Blennow, O.; Alm, J.; Björklund, A.; Malmberg, K.J.; Mougliakakos, D.; Le Blanc, A.; Oefner, P.J.; Labopin, M.; Ljungman, P.; et al. Increased incidence of chronic GvHD and CMV disease in patients with vitamin D deficiency before allogeneic stem cell transplantation. Bone Marrow Transplant. 2015, 50, 1217–1223. [CrossRef] [PubMed]
181. Hansson, M.E.; Norlin, A.C.; Omazic, B.; Wikström, A.C.; Bergman, P.; Winiarski, J.; Remberger, M.; Sundin, M. Vitamin D levels affect outcome in pediatric hematopoietic stem cell transplantation. *Biol. Blood Marrow Transplant.* **2014**, *20*, 1537–1543. [CrossRef] [PubMed]

182. Caballero-Velázquez, T.; Montero, I.; Sánchez-Guijo, F.; Parody, R.; Saldaña, R.; Valcarcel, D.; López-Godino, O.; Ferra, I.; Coll, C.; Cuesta, M.; et al. Immunomodulatory effect of vitamin D after allogeneic stem cell transplantation: Results of a prospective multicenter clinical trial. *Clin. Cancer Res.* **2016**, *22*, 5673–5681. [CrossRef] [PubMed]